Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load

Intervirology

Volumn 47, Issue 1, 2004, Pages 19-25

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Someya, Takashi ^a   Hosaka, Tetsuya ^a   Kobayashi, Mariko ^a   Sezaki, Hitomi ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; HCV genotype 1b; Long term interferon therapy

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; VIRUS GENOME; VIRUS LOAD;

ADULT; AGED; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 12144291593     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076638     Document Type: Article

References (37)

1. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-938.
2. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcome after transfusion-associated hepatitis C virus infection. N Engl J Med 1995;332:1463-1466.
3. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiurentino G, Craxi A, Cicaglione A, Giuseppetti R: Hepatitis C virus as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case control study. Ann Intern Med 1992;116:97-102.
4. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K, Iwasaki S, Matsumoto T, Kobayashi M, Kumada H: Factors predictive of response interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
5. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Hayashi Y, Shibata M, Morishima T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-299.
6. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, Kumada T: Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992;15:37-41.
7. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, J Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double blind placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
8. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C: Comparison of 1 or 3 MU of interferon alfa-2β and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991;101:497-502.
9. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, SakaiY, Kobayashi M, Unakami M, Morinaga T, Kumada H: Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-1043.
10. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Yun ZB, Weiland O: Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2β treatment. Hepatology 1995;21:918-922.
11. Yoshioka K, Yano M, Kusakabe A, Hirofuji H, Fuji A, Kuriki J, Arao M, Murase K, Kidokoro R, Kakumu S: Randomized controlled trial of lymphoblastoid interferon α for chronic hepatitis C. Am J Gastroenterol 1999;94:164-168.
12. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okada M, Hino K, Okita K: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.
13. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Mishikawa M, Seki K, Matsuzawa Y: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C: Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
14. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-659.
15. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
16. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PO, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
17. Noubaum JB, Pol S, Nalpas B, Landais P, Berthlot P, Brechot C: Hepatitis C virus type 1b infection in France and Italy. Ann Intern Med 1995;122:161-168.
18. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kurada H, Tanaka N, Arakawa Y, Omata M: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558-566.
19. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Kumada H: Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-225.
20. McHuchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman Z, Ling MH, Cort S, Albrecht JK: Interferon alfa-2β alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
21. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V,Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha 2β plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2β plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
22. Reichard O, Norkrans G, Fryden A: Randomised, double-blind, placebo controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
23. Tsubota A, Akuta A, Suzuki F, Suzuki Y, Someya T, Kobayashi M, Arase Y, Saitoh S, Ikeda K, Kumada H: Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology. 2002;45:33-42.
24. Suzuki H, Tango T, Consensus Interferon Group: A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol R 2002;22:1-12.
25. Giuseppe B, Giorgio B: Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol 2002;14:477-483.
26. Zeuzem S, Feinman SV, Rasenack J, Heathcote ej, Lai My, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferonα-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
27. Lindsay KL, Trepo C, Heintges T, Shiffmann ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK: A randomized, doubled-blinded trial comparing pegylated interferonα-2β to interferon α-2β as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
28. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Matsuzawa M, Yoshihara H, Kishida Y: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21:291-297.
29. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;32:1457-1462.
30. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2β for 60 weeks. Hepatology 1994;19:280-285.
31. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, Gallo V, Chiandussi L, Donadon V, Spirito F, Mangia A, Andriulli A: Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon 2b for chronic hepatitis type C. J Hepatol 1997;27:56-62.
32. Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Kobayashi M, Suzuki F, Kumada H: Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003;38:158-163.
33. Garson JA, Tedder RS, Briggs M, Tuke P, Ring C, Machin SJ, Tedder RS: Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and predictor of infectivity. Lancet 1990;335:1419-1422.
34. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg, Collins M, Urdea M, Sauchez-Pescador R: Accurate quantification of hepatitis C virus (HCV) RNA from HCV-genotypes by using branched-DNA technology. J Microbiol 1996;34:901-907.
35. Desmet V J, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
36. Dusheiko G, Schmilovitzs-Weiss H, Brown D, McOmish F, Yap P-l, Sherlock S, McIntyre N, Simmonds P: Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-18.
37. Mellor J, Holmes EC, Jarivis LM, Yap PL, Simmonds P, International HCV Collaborative Study Group: Investigation of the pattern of hepatitis. C virus sequence diversity in different geographical regions: Implications for virus classification. J Gen Virol 1995;76:2493-2507.